• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: AAN 2024

New developments in epilepsy: focus on cenobamate

May 2, 2024  

Treatment initiation with a higher-efficacy DMT: update from AAN

April 25, 2024  

REPORT FROM AAN 2024 – WEDNESDAY, APRIL 17

April 17, 2024  

REPORT FROM AAN 2024 – TUESDAY, APRIL 16

April 16, 2024  

REPORT FROM AAN 2024 – MONDAY, APRIL 15

April 15, 2024  

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • Ultomiris (ravulizumab) now publicly reimbursed in gMG posted on April 7, 2026
  • Ofatumumab – new data on efficacy and safety posted on April 14, 2025
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions